We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+20.24%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$216M
AUM Growth
-$32M
Cap. Flow
-$54.4M
Cap. Flow %
-25.19%
Top 10 Hldgs %
70.66%
Holding
99
New
11
Increased
15
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$2.87M
2
ALKS icon
Alkermes
ALKS
+$2.27M
3
MRSN
Mersana Therapeutics
MRSN
+$2.12M
4
TGTX icon
TG Therapeutics
TGTX
+$1.47M
5
BHVN icon
Biohaven
BHVN
+$1.37M

Top Sells

Rank Stock Value
1
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$17.4M
2
CLMT icon
Calumet Specialty Products
CLMT
+$11.7M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.96M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$5.54M
5
VRNA
Verona Pharma
VRNA
+$4.09M

Sector Composition

Rank Sector Weight
1 Healthcare 41.34%
2 Materials 20.5%
3 Financials 18.92%
4 Communication Services 13.33%
5 Technology 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.4B
$1.34M 0.62%
+45,000
New +$1.47M
VERA icon
27
Vera Therapeutics
VERA
$2.76B
$1.32M 0.61%
26,000
– –
CLOZ icon
28
Panagram BBB-B CLO ETF
CLOZ
$764M
$1.27M 0.59%
47,807
– –
BHVN icon
29
Biohaven
BHVN
$2.32B
$1.25M 0.58%
+110,720
New +$1.37M
BMY icon
30
Bristol-Myers Squibb
BMY
$124B
$1.19M 0.55%
22,000
-5,000
-19% -$241K
MDGL icon
31
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.16M 0.54%
2,000
– –
ADMA icon
32
ADMA Biologics
ADMA
$2.02B
$1.1M 0.51%
+60,200
New +$1.01M
BIIB icon
33
Biogen
BIIB
$30.4B
$1.06M 0.49%
6,000
+4,000
+200% +$653K
OBIO icon
34
Orchestra BioMed
OBIO
$220M
$1.04M 0.48%
250,000
+55,000
+28% +$222K
IBB icon
35
iShares Biotechnology ETF
IBB
$9.39B
$928K 0.43%
5,500
+1,000
+22% +$162K
SLDB icon
36
Solid Biosciences
SLDB
$858M
$916K 0.42%
162,440
– –
LENZ
37
LENZ Therapeutics
LENZ
$162M
$860K 0.4%
53,732
-28,268
-34% -$824K
PFE icon
38
Pfizer
PFE
$143B
$805K 0.37%
32,337
-42,200
-57% -$1.06M
RZLT icon
39
Rezolute
RZLT
$444M
$802K 0.37%
340,000
+65,000
+24% +$510K
MSFT icon
40
Microsoft
MSFT
$2.93T
$774K 0.36%
1,600
– –
AAPL icon
41
Apple
AAPL
$4.9T
$678K 0.31%
2,494
– –
EOLS icon
42
Evolus
EOLS
$377M
$661K 0.31%
+99,338
New +$673K
NKTR icon
43
Nektar Therapeutics
NKTR
$2.31B
$655K 0.3%
+15,500
New +$867K
IBM icon
44
IBM
IBM
$200B
$634K 0.29%
2,142
– –
SRRK icon
45
Scholar Rock
SRRK
$6.33B
$613K 0.28%
13,913
+4,913
+55% +$184K
PTHS
46
Pelthos Therapeutics
PTHS
$93.8M
$598K 0.28%
19,281
+13,169
+215% +$380K
CNQ icon
47
Canadian Natural Resources
CNQ
$91.5B
$569K 0.26%
16,800
– –
CNTB
48
Connect Biopharma Holdings
CNTB
$150M
$564K 0.26%
+200,000
New +$427K
XENE icon
49
Xenon Pharmaceuticals
XENE
$6.6B
$491K 0.23%
10,962
– –
AGIO icon
50
Agios Pharmaceuticals
AGIO
$2.36B
$490K 0.23%
+18,000
New +$632K
1
2
3 4

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
TT
TI-Trust Quincy, Illinois $168M AUM 24.32% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return

David M. Knott Jr's Q4 2025 Portfolio in Review

As of Q4 2025, David M. Knott Jr held 99 positions worth $216M, down 13% from $248M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

David M. Knott Jr withdrew a net $54.4M in Q4 2025, closing 12 positions and reducing 20 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $5.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 35% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in Cogent Biosciences worth $3.62M.

  • David M. Knott Jr's largest Q4 2025 buy was Cogent Biosciences: 102,000 shares worth $3.62M.
  • David M. Knott Jr added most to Alkermes in Q4 2025, an estimated $2.27M increase.
  • David M. Knott Jr's biggest Q4 2025 reduction was Janus Henderson AAA CLO ETF, cutting an estimated $17.4M.
  • David M. Knott Jr fully exited Avadel Pharmaceuticals in Q4 2025, selling an estimated $5.54M.
  • David M. Knott Jr's ten largest holdings make up 71% of its $216M portfolio in Q4 2025.
  • David M. Knott Jr opened 11 new positions and closed 12 in Q4 2025.
  • David M. Knott Jr's portfolio value fell 13% quarter-over-quarter to $216M.

Based on David M. Knott Jr's 13F filing for Q4 2025, filed 12 Feb 2026.